Sandoz ’s Erelzi available for multiple inflammatory disease treatment in Canada
Novartis division Sandoz has made its Erelzi (etanercept) therapy available for the treatment of multiple inflammatory diseases for patients in Canada. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 21, 2017 Category: Pharmaceuticals Source Type: news
Pfizer revenue misses on lower Prevnar, Enbrel sales
(Reuters) - Pfizer Inc reported quarterly revenue on Tuesday that missed Wall Street estimates, driven by lower demand for its rheumatoid arthritis treatment Enbrel and pneumonia vaccine Prevnar. (Source: Reuters: Health)
Source: Reuters: Health - August 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Pfizer quarterly revenue slips 2 percent
(Reuters) - Pfizer Inc reported a nearly 2 percent drop in quarterly revenue on Tuesday, driven by lower demand for its rheumatoid arthritis treatment Enbrel and pneumonia vaccine Prevnar. (Source: Reuters: Health)
Source: Reuters: Health - August 1, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Saving Vanessa, part 1: A mystery rash, a stroke and an epic rescue
Vanessa’s rash first appeared on her arms and legs when she 3 or 4 months old. It was red and bumpy and went away when she was sick with a virus, which happened often. Then it would come back. The dermatology team she saw at Boston Children’s Hospital was puzzled.
“I was expecting they were going to think it was nothing, but they took it very seriously,” says Katherine Bell, one of Vanessa’s mothers. “They took a biopsy and very quickly realized they had no idea what it was.”
Vanessa’s case was even featured at a regional dermatology conference where doctors take up mystery patients. “A hundred to 150 der...
Source: Thrive, Children's Hospital Boston - July 25, 2017 Category: Pediatrics Authors: Nancy Fliesler Tags: Diseases & Conditions Our Patients’ Stories Dr. Carolyn Rogers Dr. Pui Lee Dr. Robert Sundel Dr. Scellig Stone Dr. Todd Lyons stroke Source Type: news
Novartis unit Alcon posts modest Q2 gain
(Reuters) — Long-suffering Novartis (NYSE:NVS) unit Alcon‘s sales growth accelerated in the second quarter, boosting options for the business including a possible disposal, CEO Joe Jimenez said today.
The eye care subsidiary’s sales rose 1% to $1.5 billion, including intraocular lens revenues, which grew for the first time in the second quarter since 2014. Spending continued to promote products with eye surgeons, resulting in a $19 million operating loss.
Novartis has been reviewing Alcon for a possible disposal, with an update slated for this year. All options are under consideration, Jimenez reiterated tod...
Source: Mass Device - July 18, 2017 Category: Medical Devices Authors: Brad Perriello Tags: MassDevice Earnings Roundup Mergers & Acquisitions Optical/Ophthalmic Wall Street Beat Alcon Novartis Source Type: news
Novartis gets European OK for biosimilar of Amgen's Enbrel
ZURICH (Reuters) - Novartis's generics unit Sandoz said the European Commission approved Erelzi, its biosimilar to Amgen's Enbrel, to treat inflammatory diseases such as rheumatoid arthritis, psoriasis, and psoriatic arthritis. (Source: Reuters: Health)
Source: Reuters: Health - June 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
In Rheumatoid Arthritis, Adding a Biologic Agent Before Trying Triple Therapy Likely Not Cost-Effective (FREE)
By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH
For patients with active rheumatoid arthritis despite methotrexate therapy, adding a biologic agent (e.g., etanercept) before trying triple therapy would lead to substantial cost increases without much … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 30, 2017 Category: Primary Care Source Type: news
Cost controls help offset lower Amgen first-quarter drug sales
(Reuters) - Amgen Inc on Wednesday reported higher-than-expected first-quarter profit as cost controls helped offset a sharp drop in sales of Enbrel, its blockbuster rheumatoid arthritis and psoriasis drug. (Source: Reuters: Health)
Source: Reuters: Health - April 26, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Your NEJM Group Today: Histology Rings True / Probiotics for C. diff / Illinois IM Opportunity (FREE)
By the Editors
Here ' s today ' s offering from NEJM Group:NEJM Clinical Practice Center: Clinical Problem-Solving: A 58-year-old man with nonerosive rheumatoid arthritis who was being treated with etanercept … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - March 6, 2017 Category: Primary Care Source Type: news
Amgen Reports Fourth Quarter And Full Year 2016 Financial Results
THOUSAND OAKS, Calif., Feb. 2, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2016. Key results include:
For the fourth quarter, total revenues increased 8 percent versus the fourth quarter of 2015 to $6.0 billion.
Product sales grew 6 percent driven by Enbrel® (etanercept), Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib).
For the full year, total revenues increased 6 percent to $23.0 billion, with 5 percent product sales growth.
GAAP earnings per share (EPS) increased 9 percent in the fourth quarter to $2....
Source: Amgen News Release - February 2, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Novartis says court battle will delay its Enbrel copy until 2018 at least
ZURICH (Reuters) - The Novartis copy of Amgen's blockbuster psoriasis drug Enbrel will not go on sale before 2018 at the earliest because of the U.S. company's patent protection challenge, the Swiss drugmaker's head of generics told Reuters. (Source: Reuters: Health)
Source: Reuters: Health - January 25, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Slight, Nonsignificant CV Risk with Actemra vs Enbrel
(MedPage Today) -- Few events seen with either agent (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - November 29, 2016 Category: Journals (General) Source Type: news
Enbrel (Etanercept) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 18, 2016 Category: Drugs & Pharmacology Source Type: news
Actemra Carries Slight Increase in Heart Risk vs. Enbrel
(MedPage Today) -- But efficacy, too, must be weighed in treatment decisions (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 17, 2016 Category: Cardiology Source Type: news
FDA OKs Etanercept (Enbrel) for Kids With Plaque Psoriasis FDA OKs Etanercept (Enbrel) for Kids With Plaque Psoriasis
Etanercept becomes the first biologic approved for children aged 4 years and older with moderate-to-severe plaque psoriasis.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 8, 2016 Category: Dermatology Tags: Dermatology News Alert Source Type: news
